Skip to main content

Table 2 Characteristics of study participants with versus without bone metastatic disease

From: A prospective study determining and comparing the diagnostic accuracy of fluoride-PET/CT, choline-PET/CT, whole-body bone SPECT/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer

Parameter

Bone metastatic disease (n = 62)

No bone metastatic disease (n = 151)

p value

PSA

 Mean PSA at primary diagnosis (ng/mL)

264 (range:3–7000)

35 (range:1–1000)

< 0.001b

 Median PSA at primary diagnosis (ng/mL)

32 (IQR:16–118)

14 (IQR:8–31)

 

 Mean PSA at time of study inclusion (ng/mL)

28 (range:0.1–173)

14 (range:0.1–91)

0.01b

 Median PSA at time of study inclusion (ng/mL)

16 (IQR:5–35)

9 (IQR:4–17)

 

Gleason grade groupsa

< 0.001c

 Gleason grade group 1 (Gleason score: 3 + 3)

5 (8)

24 (16)

 

 Gleason grade group 2 (Gleason score: 3 + 4)

6 (10)

34 (23)

 

 Gleason grade group 3 (Gleason score: 4 + 3)

8 (13)

35 (23)

 

 Gleason grade group 4 (Gleason score: 4 + 4, 3 + 5, 5 + 3)

14 (23)

26 (17)

 

 Gleason grade group 5 (Gleason score: 4 + 5, 5 + 4, 5 + 5)

23 (37)

30 (20)

 

 NA

6 (10)

2 (1)

 
  1. Unless otherwise indicated, data are numbers of patients with percentages in parenthesis
  2. NA not available, PSA prostate specific antigen, IQR interquartile range
  3. aInternational Society of Urological Pathology (ISUP) 2014 Gleason grade groups (Epstein et al. 2016)
  4. bMann-Whitney U test
  5. cFisher’s exact test